



Josef Škarda

Kontakt

Josef Škarda

Publikationen (6)

Gachechiladze M, Überall I, Skanderová D, Matchavariani J, Ibrahim M, Shani I, Smičková P, Kolek V, Cierna L, Kleine-Tebbe J, Stahel R, Joerger M, Soltermann A, Škarda J. LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma. *Lung Cancer* 2021; 156:129-135.

Gachechiladze M, Škarda J, Bouchalova K, Soltermann A, Jörger M. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors. *Front Oncol* 2020; 10:581217.

Gachechiladze M, Soltermann A, Rulle U, Weder W, Stahel R, Kolář Z, Shani I, Hajduch M, Vbrková J, Vojta P, Smičková P, Kolek V, Überall I, Skanderová D, Škarda J, Jörger M. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. *Lung Cancer* 2020; 147:30-38.

Überall I, Gachechiladze M, Jörger M, Anděl J, Smičková P, Kolek V, Grygárková I, Škarda J. Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer. *Lung Cancer* 2019; 129:85-91.

Gachechiladze M, Škarda J, Soltermann A, Jörger M. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. *Int J Cancer* 2017; 141:1286-1294.

Gachechiladze M, Soltermann A, Weder W, Stahel R, Baty F, Kolář Z, Bouchal J, Langová K, Grygárková I, Kolek V, Škarda J, Jörger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. *Lung Cancer* 2017; 105:31-38.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch